14 Supplementary materials Supplementary Figure 1. Study set-up of the COIMBRA and APRICOT studies. Blue tiles are only performed for the COIMBRA study, yellow tiles only for the APRICOT study and green tiles overlap between the studies. Dashed lines indicate patients can choose whether to participate in these study procedures. APRICOT in- and exclusion criteria For the APRICOT study patient additionally had to have an expected survival of ≥ 5 months (as determined by the Graded Prognosis Assessment score). Patients were not eligible if they had standard contraindications for 3T MRI scanning and/ or use of the RespirAct RA-MRTM MRI UNIT, had medical contraindications to limited hypercapnia, were unwilling/unable to cooperate with breathing maneuvers or keeping still, were noncompliant with prescribed anti-seizure medication, had severe neurological or psychiatric diseases not related to the primary malignancy or BMs, had a history of cerebrovascular disease, used >4 mg dexamethasone per day non-prophylactically, had cardiovascular disease, pulmonary disease, concurrent severe or uncontrolled medical disease, history of bleomycin treatment, a body weight <30 kg or >100 kg or were pregnant. Semi-structured interview Physical complaints (yes/no) • Headache (e.g. uni- or bilateral pain) • Motor problems (e.g. difficulties using arm(s)/leg(s)) • Sensory problems (e.g. different experience of touch, different sensation of warm/cold) • Visual problems (e.g. not being able to see part of the visual field, seeing blurry) A
RkJQdWJsaXNoZXIy MTk4NDMw